New Horizons in the Treatment of Osteosarcoma

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging

Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,531

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma

Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948

A System for the Surgical Staging of Musculoskeletal Sarcoma

Enneking, W. F., Spanier, S. S., & GOODMAN, M. A. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198011000-00013 · Cited by 2,661

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414

Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393

Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

Bielack, S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.776 · Cited by 2,391

Mutational Processes Molding the Genomes of 21 Breast Cancers

Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355

The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity

Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004

Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

Kager, L., Zoubek, A., Pötschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., Branscheid, D., Kotz, R., Salzer-Kuntschik, M., Winkelmann, W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.132 · Cited by 934

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours

Ma, X., Liu, Y., Liu, Y., Alexandrov, L. B., Edmonson, M. N., Gawad, C., Zhou, X., Li, Y., Rusch, M. C., Easton, J., et al. (2018) · Nature · doi:10.1038/nature25795 · Cited by 901

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752

Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas

Donehower, L. A., Soussi, T., Korkut, A., Liu, Y., Schultz, A., Cardenas, M., Li, X., Babur, Ö., Hsu, T., Lichtarge, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.001 · Cited by 724

CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA

COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 717

Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate

Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D. L., Bernstein, M. L., Conrad, E. U., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Smeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D., Gorlick, R., Janeway, K. A., Ingleby, F. C., Anninga, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.027 · Cited by 704

Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery

Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6 · Cited by 584

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481

Coley's toxins, tumor necrosis factor and cancer research: A historical perspective

Wiemann, B., & Starnes, C. O. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90023-x · Cited by 466

Genome-Informed Targeted Therapy for Osteosarcoma

Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1152 · Cited by 452

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Bielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422

Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651

Goorin, A. M., Schwartzentruber, D. J., Devidas, M., Gebhardt, M. C., Ayala, A. G., Harris, M. B., Helman, L. J., Grier, H. E., & Link, M. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.165 · Cited by 394

DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis

Taylor, B., Nik‐Zainal, S., Wu, Y. L., Stebbings, L. A., Raine, K. M., Campbell, P. J., Rada, C. A., Stratton, M. R., & Neuberger, M. S. (2013) · eLife · doi:10.7554/elife.00534 · Cited by 376

Osteogenic Sarcoma under the Age of Twenty-one

Marcove, R. C., Miké, V., HAJEK, J. V., LEVIN, A. G., & Hutter, R. V. P. (1970) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-197052030-00001 · Cited by 365

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

Kovac, M., Blattmann, C., Ribi, S., Smida, J., Mueller, N. S., Engert, F., Castro-Giner, F., Weischenfeldt, J., Kovacova, M., Krieg, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9940 · Cited by 353

Association Between Osteosarcoma and Deleterious Mutations in the RECQL4 Gene in Rothmund-Thomson Syndrome

Wang, L. L., Gannavarapu, A., Kozinetz, C. A., Levy, M. L., Lewis, R. A., Chintagumpala, M. M., Ruiz-Maldanado, R., Contreras-Ruiz, J., Cunniff, C., Erickson, R. P., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.669 · Cited by 338

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

Mross, K. B., Frost, A., Steinbild, S., Hedbom, S., Büchert, M., Fasol, U., Unger, C., Krätzschmar, J., Heinig, R., Boix, O., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1900 · Cited by 335

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30742-3 · Cited by 331

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

Italiano, A., Mir, O., Mathoulin-Pelissier, S., Penel, N., Piperno-Neumann, S., Bompas, E., Chevreau, C., Duffaud, F., Entz-Werlé, N., Saada, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30825-3 · Cited by 326

Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry

Vlachos, A., Rosenberg, P. S., Atsidaftos, E., Alter, B. P., & Lipton, J. M. (2012) · Blood · doi:10.1182/blood-2011-08-375972 · Cited by 309

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3

Lu, Y., Parker, L. L., Lu, T., Zheng, Z., Toomey, M. A., White, D. E., Yao, X., Li, Y. F., Robbins, P. F., Feldman, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5463 · Cited by 288

CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment

Fujiwara, T., Yakoub, M. A., Chandler, A., Christ, A. B., Yang, G., Ouerfelli, O., Rajasekhar, V. K., Yoshida, A., Kondo, H., Hata, T., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0591 · Cited by 279

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02374 · Cited by 268

Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma

Behjati, S., Tarpey, P. S., Haase, K., Ye, H., Young, M. D., Alexandrov, L. B., Farndon, S. J., Collord, G., Wedge, D. C., Martincorena, I., et al. (2017) · Nature Communications · doi:10.1038/ncomms15936 · Cited by 261

Neoadjuvant chemotherapy for high‐grade central osteosarcoma of the extremity: Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor

Bacci, G., Bertoni, F., Longhi, A., Ferrari, S., Forni, C., Biagini, R., Bacchini, P., Donati, D., Manfrini, M., Bernini, G., et al. (2003) · Cancer · doi:10.1002/cncr.11456 · Cited by 253

Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243

Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma

Mirabello, L., Zhu, B., Koster, R., Karlins, E., Dean, M., Yeager, M., Gianferante, M., Spector, L. G., Morton, L. M., Karyadi, D., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0197 · Cited by 243

Children's Oncology Group's 2013 blueprint for research: Bone tumors

Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates

Purcell, J. W., Tanlimco, S. G., Hickson, J. A., Fox, M., Sho, M., Durkin, L. M., Uziel, T., Powers, R., Foster, K., McGonigal, T. P., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0327 · Cited by 213

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward

Lagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O., Widemann, B. C., Zwerdling, T., Bomgaars, L., Langevin, A.-M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5381 · Cited by 190

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

Krishnadas, D. K., Shusterman, S., Bai, F., Diller, L., Sullivan, J. E., Cheerva, A. C., George, R. E., & Lucas, K. G. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1731-3 · Cited by 176

Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma

Roth, M. E., Linkowski, M., Tarim, J., Piperdi, S., Sowers, R. S., Geller, D., Gill, J. B., & Gorlick, R. G. (2013) · Cancer · doi:10.1002/cncr.28461 · Cited by 174

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study

Le Cesne, A., Marec-Berard, P., Blay, J.-Y., Gaspar, N., Bertucci, F., Penel, N., Bompas, E., Cousin, S., Toulmonde, M., Bessede, A., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.018 · Cited by 174

Earliest hominin cancer: 1.7-million-year-old osteosarcoma from Swartkrans Cave, South Africa

Odes, E. J., Randolph-Quinney, P. S., Steyn, M., Throckmorton, Z., Smilg, J. S., Zipfel, B., Augustine, T. N., de Beer, F., Hoffman, J. W., Franklin, R. D., et al. (2016) · South African Journal of Science · doi:10.17159/sajs.2016/20150471 · Cited by 132

Improved assembly and variant detection of a haploid human genome using single‐molecule, high‐fidelity long reads

Vollger, M. R., Logsdon, G. A., Audano, P. A., Sulovari, A., Porubskỳ, D., Peluso, P. S., Wenger, A. M., Concepcion, G. T., Kronenberg, Z. N., Munson, K. M., et al. (2019) · Annals of Human Genetics · doi:10.1111/ahg.12364 · Cited by 123

Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas

Joseph, C. G., Hwang, H., Jiao, Y., Wood, L. D., Kinde, I., Wu, J., Mandahl, N., Luo, J., Hruban, R. H., Diaz, L. A., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22114 · Cited by 110

Widespread and nonrandom distribution of DNA palindromes in cancer cells provides a structural platform for subsequent gene amplification

Tanaka, H., Bergstrom, D. A., Yao, M.-C., & Tapscott, S. J. (2005) · Nature Genetics · doi:10.1038/ng1515 · Cited by 104

Experimental adenomas and carcinomas of the large intestine behave as distinct entities: Most carcinomas arisede novo in flat mucosa

Maskens, A. P., & Dujardin‐Loits, R. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1 · Cited by 75

Cancer‐germline gene expression in pediatric solid tumors using quantitative real‐time PCR

Jacobs, J. F. M., Brasseur, F., de Kaa, C. A. H., van de Rakt, M. W. M. M., Figdor, C. G., Adema, G. J., Hoogerbrugge, P. M., Coulie, P. G., & de Vries, I. J. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.22118 · Cited by 69

Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma

Guenther, L. M., Rowe, R. G., Acharya, P. T., Swenson, D. W., Meyer, S. C., Clinton, C. M., Guo, D., Sridharan, M., London, W. B., Grier, H. E., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26896 · Cited by 66

Role of Tumor-Associated Macrophages in Sarcomas

Fujiwara, T., Healey, J. H., Ogura, K., Kondo, H., Kondo, H., Hata, T., Tazawa, H., Nakata, E., Kunisada, T., Fujiwara, T., et al. (2021) · Cancers · doi:10.3390/cancers13051086 · Cited by 61

The breakage–fusion–bridge (BFB) cycle as a mechanism for generating genetic heterogeneity in osteosarcoma

Selvarajah, S., Yoshimoto, M., Park, P. C., Maire, G., Paděrová, J., Bayani, J., Lim, G., Al-Romaih, K. I., Squire, J. A., & Zieleńska, M. (2006) · Chromosoma · doi:10.1007/s00412-006-0074-4 · Cited by 58

Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Literature review and guidelines of the bone group (GROUPOS) of the French sarcoma group and bone tumor study group (GSF-GETO/RESOS)

Gomez‐Brouchet, A., Mascard, É., Siegfried, A., Pinieux, G. D. B. D., Gaspar, N., Bouvier, C., Aubert, S., Marec‐Bérard, P., Piperno-Neumann, S., Marie, B., et al. (2019) · Orthopaedics & Traumatology Surgery & Research · doi:10.1016/j.otsr.2018.12.015 · Cited by 58

An integrated mBAND and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage–fusion–bridge cycle events in osteosarcoma

Lim, G., Karásková, J., Beheshti, B., Vukovic, B., Bayani, J., Selvarajah, S., Watson, S. K., Lam, W. L., Zieleńska, M., & Squire, J. A. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20157 · Cited by 57

First case of osteosarcoma in a dinosaur: a multimodal diagnosis

Ekhtiari, S., Chiba, K., Popović, S., Crowther, R., Wohl, G. R., Wong, A. K. O., Tanke, D. H., Dufault, D. M., Geen, O. D., Parasu, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30171-6 · Cited by 55

Integrated genetic and pharmacologic interrogation of rare cancers

Hong, A. L., Tseng, Y., Cowley, G. S., Jonas, O. H., Cheah, J. H., Kynnap, B. D., Doshi, M. B., Oh, C., Meyer, S. C., Church, A. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11987 · Cited by 54

LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications

Ben‐Ami, E., Perret, R. E., Huang, Y., Courgeon, F., Gokhale, P. C., Laroche‐Clary, A., Eschle, B. K., Velasco, V., Loarer, F. L., Algéo, M.-P., et al. (2020) · Cancers · doi:10.3390/cancers12030757 · Cited by 36

LRRC15 antibody‐drug conjugates show promise as osteosarcoma therapeutics in preclinical studies

Slemmons, K. K., Mukherjee, S., Meltzer, P. S., Purcell, J. W., & Helman, L. J. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28771 · Cited by 31

RECQ DNA Helicases and Osteosarcoma

Lu, L., Jin, W., & Wang, L. L. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43085-6_3 · Cited by 28

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA

Dişel, U., Madison, R. W., Abhishek, K., Chung, J., Trabucco, S. E., Matos, A. O., Frampton, G. M., Albacker, L. A., Reddy, V. P., Karadurmuş, N., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0528 · Cited by 27

Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma

Sorenson, L., Fu, Y., Hood, T., Warren, S. E., & McEachron, T. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1629779 · Cited by 20

Osteosarcoma of the extremities: Chemotherapy experience at Memorial Sloan-Kettering

Meyers, P. A., Heller, G., & Vlamis, V. (1993) · Cancer treatment and research · doi:10.1007/978-1-4615-3518-8_37 · Cited by 18

Osteosarcoma

Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660

Notch signaling pathway in cancer: from mechanistic insights to targeted therapies

Shi, Q., Xue, C., Zeng, Y., Yuan, X., Chu, Q., Jiang, S., Wang, J., Zhang, Y., Zhu, D., & Li, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01828-x · Cited by 428

Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics

Shi, P., Cheng, Z., Zhao, K., Chen, Y., Zhang, A., Gan, W., & Zhang, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01826-1 · Cited by 216

Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks

Cillo, A. R., Mukherjee, E., Bailey, N. G., Onkar, S., Daley, J. D., Salgado, C. M., Li, X., Liu, D., Ranganathan, S., Burgess, M. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1471 · Cited by 95

A tumor microenvironment-based prognostic index for osteosarcoma

Wu, C., Gong, S., Duan, Y., Deng, C., Kallendrusch, S., Berninghausen, L. K., Osterhoff, G., & Schopow, N. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00917-3 · Cited by 94

Osteosarcoma – conventional treatment vs. gene therapy

Tan, M. L., Choong, P., & Dass, C. R. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.2.7385 · Cited by 99

From biology to personalized medicine: Recent knowledge in osteosarcoma

Mohr, A., Costa, M. E. M. D., Fromigué, O., Audinot, B., Balde, T., Droit, R., Abbou, S. D., Khneisser, P., Berlanga, P., Pérez, E., et al. (2024) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2024.104941 · Cited by 13

The Genetics of Osteosarcoma

Martin, J. W., Squire, J. A., & Zieleńska, M. (2012) · Sarcoma · doi:10.1155/2012/627254 · Cited by 254

Making gene therapy for osteosarcoma a reality

Broadhead, M. L., Clark, J. C. M., Choong, P., & Dass, C. R. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.18 · Cited by 12

Genome-Informed Targeted Therapy for Osteosarcoma

Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1152 · Cited by 452